Objectives: To describe the characteristic of bladder transitional cell cancer (TCC). Material & methods: We reviewed the medical records of patients with bladder TCC admitted in Soetomo General Hospital Surabaya, from January 2008 until December 2012. The data regarding demographic characteristics, clinical presentation and staging, grading and staging based on pathological examinations results, and the management of the cancer.Results: The 126 cases, consisted of 102 men (81%) and 24 women (19%) with its ratio was 4.2 : 1. All male patients were heavy cigarette smokers. Mean age was 57.8 years, peak incidence was50-59 years. Hematuria was the mostfrequent clinical presentation (112 patients, 88.9%), urinary retention and other complaints (12 patients, 9.5%), and chronic dysuria (2 patients, 1.6%). Clinical staging was T1 as NMIBC in 7 patients (5.7%). MIBC consisted of T2 in 37 patients (30.3%), T3 in 35 patients (28.7%), T4 in 43 patients (35.2%). The pathological grading as an high-grade were 74 patients (64.3%). All patients had underwent TURBT for diagnosis and staging, followed by definitive treatment. It consisted of TURBT and chemotherapy bladder instillation in 7 patients (5.6%), radical cystectomy in 13 patients (10.3%), EBRT in 5 patients (4%), MVAC chemotherapy in 24 patients (19%), EBRT and chemotherapy with MVAC in 3 patients (2.4%). There were 74 patients (58.7%) underwent TURBT alone.Conclusion: Bladder TCC was in advanced stage when diagnosed, most of the patients received only TURBT and refused further treatment. Keywords: Bladder transitional cell cancer, characteristics, managements.
Ploeg M, Aben KKH, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009; 27: 289-93.
Global Cancer Facts and Figure. 2nd ed. Atlanta: American Cancer Society; 2011.
Burger M. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol.2013; 63: 234-41.
Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011; 306(7): 737-45.
Sobin LH, Gospodariwicz M, Wittekind (eds). TNM classification of malignant tumors, UICC International Against Cancer. 7th ed. Iowa: Wiley-Blackwell. 2009; 7: 263.
Babjuk M, Burger M, Zigeuner R. Guideline on non-muscle invasive bladder cancer (TaT1 and Cis). European Association of Urology Guidelines; 2013.
Siroky MB, Oates RD, Babayan RK. Neoplasm of the genitourinary tract. In: Handbook of Urology. 3rd ed. New York: Lippincott Williams & Wilkins. 2004; 3: 258-69.
Clark PE, Agarwal N. National comprehensive cancer network clinical practices guidelines oncology, bladder cancer, version 1. 2014.http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
Hall MC, Chang SS. Bladder cancer, Guidelines for the management of nonmuscle invasive bladder cancer: (Stage Ta, T1, Tis): 2007 updates. https://www.auanet.org/common/pdf/education/ clinical-guidance/bladder-cancer.pdf
Vrooman OPJ, Witjes JA. Urinary markers in bladder cancer. Eur Urol. 2008; 53: 909-16.
Tetu B. Diagnosis of urothelial carcinoma from urine. Modern Pathology. 2009; 22: 53-4.
Rhijn van BWG, Poel van der HG, Kwast van der TH. Cytology and urinary markers for the diagnosis of bladder cancer. Eur Urol. 2009; 8: 536-41.
Belmunt J. Bladder cancer: ESMO clinical practices guidelines for diagnosis, treatment, and follow-up. Ann of Oncol. 2011; 22(6): 45-9.
Yafi FA, Kassouf W. Radical cystectomy is the treatment of choice for invasive bladder cancer. Canadian Urol Association J. 2009; 3(5): 409-12.
Stein JP. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J of Clin Oncol. 2001; 19(3): 666-75.
Stenzl A. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011; 59: 1009-18.
Boccardo F, Palmen L. Adjuvant chemotherapy of bladder cancer. Ann of Oncol. 2006; 17(5): 129-32.
Roberts JT. Long-term survival results of randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann of Oncol. 2006; 17(5): 118-22.
Costantini C, Millard F. Update on chemotherapy in the treatment of urothelial carcinoma. The Scientific World J. 2011; 11: 1981-94.
James ND. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012; 366(16): 1477-88.